Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression

Journal of Virology

Volumn 72, Issue 12, 1998, Pages 9835-9843

  Mah, Cathryn ^a,b,c   Qing, Keyun ^a,b,c   Khuntirat, Benjawan ^a,b,c   Ponnazhagan, Selvarangan ^a,b,c   Wang, Xu Shan ^a,b,c   Kube, Dagmar M ^a,b,c   Yoder, Mervin C ^b   Srivastava, Arun ^a,b,c  

^a Dept of Microbiology and Immunology ^*  (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WALTHER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; APIGENIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; HERBIMYCIN A; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAUROSPORINE; TYRPHOSTIN; VIRUS VECTOR; WORTMANNIN;

ADENOVIRUS; ARTICLE; DNA REPLICATION; GENE EXPRESSION; GENE THERAPY; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0031775223     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.12.9835-9843.1998     Document Type: Article

References (61)

1. Akiyama, T., J. Ishida, S. Nakagawa, H. Ogawara, S. Watanabe, N. Itoh, M. Shibuya, and Y. Fukami. 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262:5592-5595.
2. Alexander, I. E., D. W. Russell, A. M. Spence, and A. D. Miller. 1996. Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by recombinant adeno-associated virus vectors. Hum. Gene Ther. 7:841-850.
3. Barnes, S., and G. T. Peterson. 1995. Biochemical targets of the isoflavone genistein in tumor cell lines. Soc. Exp. Biol. Med. 280:103-109.
4. Berns, K. I., and R. A. Bohenzky. 1987. Adeno-associated viruses: an update. Adv. Virus Res. 32:243-307.
5. Berns, K. I., and C. Giraud. 1996. Biology of adeno-associated virus. Curr. Top. Microbiol. Immunol. 218:1-23.
6. Boonstra, J., P. Rijken, B. Humbel, F. Cremers, A. Verkleij, and P. van Bergen en Henegouwen. 1995. The epidermal growth factor. Cell Biol. Int. 19:413-430.
7. Carlo-Stella, C., E. Regazzi, D. Garau, L. Mangoni, M. T. Rizzo, A. Bonati, G. Dotti, C. Almici, and V. Rizzoli. 1996. Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. Br. J. Haematol. 93:551-557.
8. Constantinou, A., and E. Huberman. 1995. Genistein as an inducer of tumor cell differentiation: possible mechanisms of action. Soc. Exp. Biol. Med. 203:109-115.
9. Couldwell, W. T., D. R. Hinton, S. He, T. C. Chen, I. Sebat, M. H. Weiss, and R. E. Law. 1994. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett. 345:43-46.
10. Faaland, C. A., F. H. Mermelstein, J. Hayashi, and J. D. Laskin. 1991. Rapid uptake of tyrphostin into A431 human epidermoid cells is followed by delayed inhibition of epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase activity. Mol. Cell. Biol. 11:2697-2703.
11. Fabricant, R. N., J. E. DeLarco, and G. J. Todaro. 1977. Nerve growth factor receptors on human melanoma cells in culture. Proc. Natl. Acad. Sci. USA 74:565-569.
12. Ferrari, F. K., T. Samulski, T. Shenk, and R. J. Samulski. 1996. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70:3227-3234.
13. Fisher, K. J., G.-P. Gao, M. D. Weitzman, R. DeMatteo, J. F. Burda, and J. M. Wilson. 1996. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70:520-532.
14. Fisher, K. J., K. Jooss, J. Alston, Y. Yang, S. E. Haecker, K. High, R. Pathak, S. E. Raper, and J. M. Wilson. 1997. Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3:306-312.
15. Fukazawa, H., P. M. Li, C. Yamamoto, Y. Murakami, S. Mizuno, and Y. Uehara. 1991. Specific inhibition of cytoplasmic protein tyrosine kinases by herbimycin A in vitro. Biochem. Pharmacol. 42:1661-1671.
16. Gamou, S., J. Hunts, H. Harigai, H. Hirohashi, Y. Shimosato, I. Pastan, and N. Shimizu. 1987. Molecular evidence for the lack of epidermal growth factor receptor gene expression in small cell lung carcinoma cells. Cancer Res. 47:2668-2673.
17. Gazit, A., P. Yaish, C. Gilon, and A. Levitzki. 1989. Tyrphostin I: synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 32:2344-2352.
18. Ghiringhelli, P. D., and V. Romanowski. 1994. Quick methylene blue staining for visualizing virus plaques in titration experiments. BioTechniques 17:464-465.
19. Giard, D. J., S. A. Aaronson, G. J. Todaro, P. Arnstein, J. H. Kersey, H. Dosik, and W. P. Parks. 1973. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 51:1417-1423.
20. Kaplitt, M. G., P. Leone, R. J. Samulski, X. Xiao, D. W. Pfaff, K. L. O'Malley, and M. J. During. 1994. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8:148-153.
21. Kessler, P. D., G. M. Podsakoff, X. Chen, S. A. McQuiston, P. C. Colosi, L. A. Matelis, G. J. Kurtzman, and B. J. Byrne. 1996. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA 93:14082-14087.
22. Kovalenko, M., A. Gazit, A. Böhmer, C. Rorsman, L. Rönnstrand, C. H. Heldin, J. Waltenberger, F. O. Böhmer, and A. Levitzki. 1994. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54:6106-6114.
23. Kube, D. M., and A. Srivastava. 1997. Quantitative DNA slot blot analysis: inhibition of DNA binding to membranes by magnesium ions. Nucleic Acids Res. 25:3375-3376.
24. Kube, D. M., S. Ponnazhagan, and A. Srivastava. 1997. Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells. J. Virol. 71:7361-7371.
25. Kuo, M. L., and N. C. Yang. 1995. Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem. Biophys. Res. Comm. 212:767-775.
26. Levitzki, A. 1990. Tyrphostin: potential anti-proliferative agents and novel molecular tools. Biochem. Pharmacol. 40:913-918.
27. Levitzki, A., A. Gazit, N. Osherov, I. Posner, and C. Gilon. 1991. Inhibition of protein tyrosine kinases by tyrphostin. Methods Enzymol. 201:347-361.
28. Lim, R. W., and S. D. Hauschka. 1984. A rapid decrease in epidermal growth factor binding capacity accompanies the terminal differentiation of mouse myoblasts in vitro. J. Cell Biol. 98:739-747.
29. Livneh, E., R. Prywes, O. Kashles, N. Reiss, I. Sasson, Y. Mory, A. Ullrich, and J. Schlessinger. 1986. Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells. J. Biol. Chem. 261:12490-12497.
30. Lyall, R. M., A. Zilberstein, A. Gazit, C. Gilon, A. Levitzki, and J. Schlessinger. 1989. Tyrphostin inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J. Biol. Chem. 264:14503-14509.
31. McCown, T. J., X. Xiao, J. Li, G. R. Breese, and R. J. Samulski. 1996. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713:99-107.
32. McGlynn, E., M. Becker, H. Mett, S. Reutner, R. Cozens, and N. B. Lydon. 1992. Large scale purification and characterization of a recombinant epidermal growth factor receptor protein tyrosine kinase. Eur. J. Biochem. 207: 265-275.
33. Miller, D. L., D. El-Ashry, A. L. Cheville, Y. Liu, S. W. McLeskey, and F. G. Kern. 1994. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for growth and progression. Cell Growth Differ. 5:1263-1274.
34. Muller, M. T. 1987. Binding of herpes simplex virus immediate-early gene product ICP4 to its own transcription start site. J. Virol. 61:858-865.
35. Muzyczka, N. 1992. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158:97-129.
36. Nahreini, P., M. J. Woody, S. Z. Zhou, and A. Srivastava. 1993. Versatile adeno-associated virus 2-based vectors for constructing recombinant virions. Gene 124:257-262.
37. Novogrodsky, A., A. Vanichkin, M. Patya, A. Gazit, N. Osherov, and A. Levitzki. 1994. Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science 264:1319-1322.
38. Okada, T., L. Sakuma, Y. Fukui, O. Hazeki, and M. Ui. 1994. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phophatidylinositol 3-kinase. J. Biol. Chem. 269:3563-3567.
39. Ponnazhagan, S., D. Erikson, W. G. Kearns, S. Z. Zhou, P. Nahreini, X.-S. Wang, and A. Srivastava. 1997. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum. Gene Ther. 8:275-284.
40. + hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. J. Virol. 71:8262-8267.
41. Ponnazhagan, S., P. Mukherjee, M. C. Yoder, X.-S. Wang, S. Z. Zhou, J. Kaplan, S. Wadsworth, and A. Srivastava. 1997. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 190:203-210.
42. Ponnazhagan, S., X.-S. Wang, M. J. Woody, F. Luo, L. Y. Kang, M. L. Nallari, N. C. Munshi, S. Z. Zhou, and A. Srivastava. 1996. Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection. J. Gen. Virol. 77:1111-1122.
43. Ponnazhagan, S., M. C. Yoder, and A. Srivastava. 1997. Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo. J. Virol. 71:3098-3104.
44. Qing, K., T. Bachelot, P. Mukherjee, X.-S. Wang, L. Peng, M. C. Yoder, P. Leboulch, and A. Srivastava. 1997. Adeno-associated virus type 2-mediated transfer of ecotropic retrovirus receptor cDNA allows ecotropic retroviral transduction of established and primary human cells. J. Virol. 71:5663-5667.
45. Qing, K., B. Khuntirat, C. Mah, D. M. Kube, X.-S. Wang, S. Ponnazhagan, S. Z. Zhou, V. J. Dwarki, M. C. Yoder, and A. Srivastava. 1998. Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J. Virol. 72:1593-1599.
46. Qing, K. Y., C. Mah, J. Hansen, S. Z. Zhou, V. J. Dwarki, and A. Srivastava. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Submitted for publication.
47. Qing, K. Y., X.-S. Wang, D. M. Kube, S. Ponnazhagan, A. Bajpai, and A. Srivastava. 1997. Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc. Natl. Acad. Sci. USA 94:10879-10884.
48. Russell, D. W., I. E. Alexander, and A. D. Miller. 1995. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA 92:5719-5723.
49. Russell, D. W., A. D. Miller, and I. E. Alexander. 1994. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. USA 91:8915-8919.
50. Samulski, R. J., L.-S. Chang, and T. Shenk. 1989. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 36:3822-3828.
51. Srivastava, A., E. W. Lusby, and K. I. Berns. 1983. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45:555-564.
52. Styren, S. D., S. T. DeKosky, J. Rogers, and E. J. Mufson. 1993. Epidermal growth factor receptor expression in demented elderly: localization to vascular endothelial cells of brain, pituitary, and skin. Brain Res. 615:181-190.
53. Summerford, C., and R. J. Samulski. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-1445.
54. Vlahos, C. J., W. F. Matter, K. Y. Hui, and R. F. Brown. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269:5241-5248.
55. Wang, X.-S., B. Khuntirat, K. Y. Qing, S. Ponnazhagan, D. M. Kube, S. Z. Zhou, V. J. Dwarki, and A. Srivastava. 1998. Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J. Virol. 72:5472-5480.
56. Wang, X.-S., S. Ponnazhagan, and A. Srivastava. 1995. Rescue and replication signals of the adeno-associated virus 2 genome. J. Mol. Biol. 250:573-580.
57. Wang, X.-S., S. Ponnazhagan, and A. Srivastava. 1996. Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. J. Virol. 70:1668-1677.
58. Wang, X.-S., K. Y. Qing, S. Ponnazhagan, and A. Srivastava. 1997. Adeno-associated virus type 2 DNA replication in vivo: mutation analyses of the D sequence in viral inverted terminal repeats. J. Virol. 71:3077-3082.
59. Weber, W., P. J. Bertics, and G. N. Gill. 1984. Immunoaffinity purification of the epidermal growth factor receptor. J. Biol. Chem. 259:14631-14636.
60. Xiao, X., J. Li, and R. J. Samulski. 1996. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70:8098-8108.
61. Yaish, P., A. Gazit, C. Gilon, and A. Levitzki. 1988. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242:933-935.